Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) CFO Houte Hans Van sold 924 shares of the firm's stock in a transaction that occurred on Monday, January 30th. The shares were sold at an average price of $11.78, for a total transaction of $10,884.72. Following the completion of the sale, the chief financial officer now owns 76,765 shares in the company, valued at approximately $904,291.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Nurix Therapeutics Trading Up 7.3 %
NASDAQ NRIX opened at $13.26 on Friday. Nurix Therapeutics, Inc. has a 12 month low of $7.52 and a 12 month high of $20.20. The company's 50 day simple moving average is $11.69 and its 200 day simple moving average is $13.45.
Get
Nurix Therapeutics alerts:
Analyst Upgrades and Downgrades
Several equities research analysts have commented on NRIX shares. HC Wainwright dropped their price target on shares of Nurix Therapeutics to $53.00 in a research note on Thursday, October 13th. SVB Leerink dropped their price target on shares of Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating on the stock in a research note on Tuesday, December 13th. Finally, Morgan Stanley started coverage on shares of Nurix Therapeutics in a research note on Tuesday, October 11th. They issued an "equal weight" rating and a $11.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $32.90.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. grew its position in Nurix Therapeutics by 11.0% in the third quarter. BlackRock Inc. now owns 3,723,090 shares of the company's stock worth $48,512,000 after buying an additional 367,743 shares during the last quarter. State Street Corp grew its position in Nurix Therapeutics by 9.2% in the third quarter. State Street Corp now owns 2,312,224 shares of the company's stock worth $30,128,000 after buying an additional 195,453 shares during the last quarter. Vanguard Group Inc. grew its position in Nurix Therapeutics by 2.3% in the third quarter. Vanguard Group Inc. now owns 2,160,866 shares of the company's stock worth $28,156,000 after buying an additional 49,370 shares during the last quarter. ARK Investment Management LLC grew its position in Nurix Therapeutics by 54.5% in the fourth quarter. ARK Investment Management LLC now owns 1,988,254 shares of the company's stock worth $21,831,000 after buying an additional 701,732 shares during the last quarter. Finally, Bain Capital Life Sciences Investors LLC grew its position in Nurix Therapeutics by 41.9% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 1,822,883 shares of the company's stock worth $23,096,000 after buying an additional 538,570 shares during the last quarter. Institutional investors and hedge funds own 91.33% of the company's stock.
Nurix Therapeutics Company Profile
(Get Rating)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
See Also
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
